Guardant Health, Inc. · NASDAQ:GH
Guardant Health — Conference Presentation (January 2020)
26 slides from Guardant Health's conference presentation, Jan 13, 2020
Slide 1: Company Overview January 13, 2020
Company Overview January 13, 2020
Slide 2: Safe Harbor
Safe Harbor Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of Guardant Health, Inc. (the “Company”) and involve known and unknown risks, uncertainties and other
Slide 3: Liquid biopsy is at the center of transforming cancer care
Liquid biopsy is at the center of transforming cancer care by unlocking data that will drive improved clinical outcomes 3
Slide 4: Patient story: stage IV non-small cell lung cancer
' Stage IV non-small cell lung cancer ' Metastatic cancer including brain metastases ' Required lung drainage prior to tissue biopsy ' Guardant360 results indicated EGFR mutation ' Started on osimertinib (Tagrisso®) immediately “I’m alive today because of Guardant.” - Star 4
Slide 5: Guardant liquid biopsy platform unlocks cancer signals in blood
Guardant liquid biopsy platform unlocks cancer signals in blood Across all 4 classes of 100K+ tests genomic alterations and MSI fuel insights High-efficiency Next-generation Learning chemistry sequencing bioinformatics engine 2-3x 1000x higher reduction in conversion sequencing efficiency error rate
Slide 6: Liquid biopsy platform poised to unlock $50B+ market opportunity
Guardant liquid biopsy platform poised to transform cancer management and unlock $50B+ market opportunity ~65M+ Individuals1 Detects early-stageearly-stage cancer $30B+2 ~15M Early-stage, Neoadjuvant / adjuvant treatment Recurrence monitoring survivors $15B2 ~700K Advanced Systemic treatment cancer
Slide 7: Realizing liquid biopsy opportunity requires more than just technology
Realizing liquid biopsy market opportunity requires significantly more than just technology $6B2 Operations & Commercial Infrastructure ' Adoption by 7,000+ oncologists ' 60+ biopharma partners Reimbursement ' 170M+ covered lives ' Medicare pan-cancer coverage1 Regulatory approval ' PMA submission '
Slide 8: Early innings of adoption in the advanced cancer market
Early innings of adoption in the advanced cancer market ® $6 Billion1 700K Patients Majority of patients do not receive guideline recommended genomic testing $2B $4B <8% <40% Biopharma Clinical NSCLC PATIENTS CRC PATIENTS tested to guidelines2 tested to guidelines3 1. U.S. Market Opportunity (estima
Slide 9: Guardant360 solves the challenges with tissue testing
Guardant360 solves the challenges with tissue testing Results of NILE support a blood-first testing paradigm 282 NSCLC Patients Prospective, Multi-Center Trial1 Standard of Care Tissue Testing vs Guideline Complete Genotyping 18% 95% Detection of NCCN Biomarkers 60 patients 77 patients Median Turn A
Slide 10: Significant catalysts for U.S. clinical reimbursement
Significant catalysts for U.S. clinical reimbursement Medicare LCD is a major milestone expanding reimbursement beyond NSCLC 170M+ Covered Lives1 Additional Medicare Additional Medicare private LCD for pan-cancer LCD coverage majority of private payor NSCLC 2 NSCLC solid tumors coverage Aug 2018 Feb
Slide 11: Strong Guardant360 clinical adoption
Strong Guardant360 clinical adoption Guardant360 test volume +89% +77% # &"#" ' +31% ' " !% " 2020 Catalysts 13,259 11,875 ' Shift to blood-first paradigm 9,521 ' Pan-cancer reimbursement 7,246 6,723 7,027 ' Progression testing ' Multiple biomarker-directed therapy approval
Slide 12: Biopharma opportunity
Biopharma opportunity $2B of the $6B therapy selection market $2 Billion1 Retrospective 1,200+ Targeted therapy, PARP, and I-O trials Clinical programs 17% Opportunity CDx ~$2 Billion 15% 130,000+ PatientsBiopharmaceutica l Opportunity Commercial Prospective 12% 60+ Pharma partners trials 56% 1.U.S.
Slide 13: Guardant Health and Amgen strategic collaboration
Guardant Health and AMGEN strategic collaboration ' 13% of all NSCLC patients harbor KRAS G12C mutations1 AMG 510 – An investigational ' Strategic collaboration to KRAS G12C inhibitor develop and support commercialization of a blood- based CDx in NSCLC for ® AMG 510 ' Seeking global approvals in U.S
Slide 14: GuardantOMNI opportunity
GuardantOMNI opportunity Well-positioned to continue momentum in 2020 1,200+ programs1 Targeted Therapy Immuno-Oncology PARP TM High-performance High-sensitivity Detection of multiple detection of genomic detection of blood- mechanisms of alterations across 500 ++based tumor homologous repair genes
Slide 15: Robust biopharma growth
Robust biopharma growth Biopharma test volume +112% +111% ' Increase in I/O and combination +61% trials have led to rapid growth in 5,285 5,280 OMNI volumes 3,762 ' Steady growth of 2,334 2,498 2,505 pharma test ASPs Q1 18 Q1 19 Q2 18 Q2 19 Q3 18 Q3 19 ASP $2,966 $3,109 $3,286 $3,827 $3,491 $4,052 1
Slide 16: LUNAR program fueled by success of GH portfolio
LUNAR program fueled by success of GH portfolio Leveraging data, operational & commercial infrastructure ! $ # ! 100,000+ tests Best-in-class technology platform 16
Slide 17: Unlocking multiple dimensions of ctDNA in blood
Unlocking multiple dimensions of ctDNA in blood to overcome the challenges of early-stage cancer detection Genomic Alterations Methylation Fragmentomics T C G A T C G 17
Slide 18: LUNAR-1 assay CLIA-validated in Q4 2019
LUNAR-1 assay CLIA-validated in Q4 2019 ASCO data demonstrates highly specific detection of minimal residual disease1 Blood only Genomic signatures Methylation signatures 100% PPV for recurrence when ctDNA detected Patients with N=43 resectable colon Survival (%) Free Recurrence cancer, post-a
Slide 19: COBRA: randomized controlled trial in early-stage colon cancer
COBRA: Randomized controlled trial to establish clinical utility in early-stage colon cancer ~1,400 Resectable Stage II Colon Cancer Patients Suitable for Active Surveillance Randomize Active Surveillance vs. ctDNA Directed Adjuvant Therapy Retrospective ctDNA ctDNA + ctDNA – 1 Analysis mFOLFOX6 Act
Slide 20: Opportunity to improve screening in many tumor types
Opportunity to improve screening in many tumor types Screening compliance rates in CRC represents a significant unmet need % of U.S. adults age 50-75 up to date with CRC screening1 1.Nov 2019 NCCRT Annual Meeting, presented by Richard Wender Chief Canc
Slide 21: LUNAR-2 assay shows high sensitivity in detecting CRC
LUNAR-2 assay shows high sensitivity in detecting CRC Addition of epigenomic signatures improves sensitivity 94%1 88%1 Genomic signatures Methylation signatures Epi+Genomic Fragmentomic signatures 105 recently diagnosed colorectal cancer Genomic patients 124 cancer-free age-matched controls
Slide 22: ECLIPSE: 10,000-patient CRC screening study initiated
ECLIPSE1: 10,000-patient CRC screening study initiated First blood-based CRC screening trial of this magnitude Prospective trial Screening Colonoscopy vs 10,000+ individuals …average risk for CRC Blood Test …aged 45-84 Evaluating performance of LUNAR-2 to detect CRC in ~100 sites in the U.S. average
Slide 23: Rapid revenue growth
Rapid revenue growth +181% +178% $61M $54M +120% $37M $19M $22M $17M Q1 18 Q1 19 Q2 18 Q2 19 Q3 18 Q3 19 23
Slide 24: Consistent improvement in gross profit margin
Consistent improvement in gross profit margin1 +20.2 +15.9 +18.5 68.8% 69.6% 63.1% 53.7% 48.6% 44.6% Q1 2018 Q1 2019 Q2 2018 Q2 2019 Q3 2018 Q3 2019 1. Gross profit margin = Gross profit divided by total revenue. Gross profit = total revenue less cost of precision oncology testing and cost of develo
Slide 25: Significant opportunities to drive future growth
Significant opportunities to drive future growth for asymptomatic + high-risk for early-stage individuals cancer patients + International survivors Expanding expansion treatment options Continued COGS increases demand for CGP ® and OpEx leverage Volume growth driven by blood- first paradigm FDA appr
Slide 26: Guardant
(@) GUARDANT
Guardant Health — Conference Presentation (January 2020) on 6ix